3 hours ago
1
Baris-Ozer/iStock via Getty Images
Iovance Biotherapeutics (NASDAQ:IOVA) shares tanked after the company failed to meet top-line as well as bottom-line expectations.
The company reported a quarterly revenue of $60M, missing estimate by $7.14M, hurt by sales of Proleukin. It also posted a loss per share of $0.33, falling short of analysts
English (US) ·